BIOFUSION (BFN).

Investors Chronicle, April, 2007

Few chief executives can be as enthusiastic about their company as Biofusion's bubbly director, David Baynes. And we can see why. The company started trading on the Alternative Investment Market (Aim) at 150p a share in February 2005 and now has a portfolio of 24 investments in research businesses, designed to commercialise university-generated intellectual property (IP).

On flotation, it signed a 10-year exclusive agreement with Sheffield University to commercialise medical life-science discoveries, followed in November 2006 by a similar deal with Cardiff University covering all its IP. As a result, the two universities control Biofusion, having 25 and 29 per cent stakes, respectively. Biofusion is now looking for a third and final link-up with one of the top...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here